Frequency of nausea and vomiting after chemotherapy [1]

American Journal of Health-System Pharmacy

Volumn 61, Issue 7, 2004, Pages 722-723

  Park, Vivian J ^a   Trovato, James A ^b  

^a NEMOURS ALFRED I DUPONT HOSPITAL FOR CHILDREN   (United States)

^b UNIVERSITY OF MARYLAND SCHOOL OF PHARMACY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIEMETIC AGENT; ANTINEOPLASTIC AGENT; DEXAMETHASONE; DOLASETRON MESILATE; METOCLOPRAMIDE;

CANCER CHEMOTHERAPY; CHEMOPROPHYLAXIS; CHEMOTHERAPY INDUCED EMESIS; CLINICAL ARTICLE; DRUG EFFICACY; HUMAN; LETTER; NAUSEA; PRACTICE GUIDELINE; PRIORITY JOURNAL; CHEMICALLY INDUCED DISORDER; DRUG THERAPY; NEOPLASM; UNITED STATES; VOMITING;

DRUG THERAPY; HUMANS; NAUSEA; NEOPLASMS; UNITED STATES; VOMITING;

EID: 3042819696     PISSN: 10792082     EISSN: None     Source Type: Journal    
DOI: 10.1093/ajhp/61.7.722     Document Type: Letter

References (4)

1. American Society of Health-System Pharmacists. ASHP therapeutic guidelines on the pharmacologic management of nausea and vomiting in adult and pediatric patients receiving chemotherapy or radiation therapy or undergoing surgery. Am J Health-Syst Pharm. 1999; 56:729-64.
2. Gralla RJ, Osoba D, Kris MG et al. Recommendations for the use of antiemetics: evidence-based, clinical practice guidelines: ASCO. J Clin Oncol. 1999; 17:2791-994.
3. Antiemetic Subcommittee of the Multinational Association of Supportive Care in Cancer. Prevention of chemotherapy- and radiotherapy-induced emesis: results of the Perugia Consensus Conference. Ann Oncol. 1998; 9:811-9.
4. Hesketh PJ, Kris MG, Grunberg SM et al. A proposal for classifying the acute emetogenicity of cancer chemotherapy. J Clin Oncol. 1997; 15:103-9.